Over the past years, Hsp90 has been deeply investigated, from both industry and academic research institutes, as new potential target for cancer and Hsp90 inhibition has, thus, become an attractive therapeutic concept to develop clinically viable antitumor agents (see http://clinicaltrilas.gov). The gene discussed is HSP90AA1; the disease is cancer.